Dec 2009 Biotech Event$ and Calendar

As posted here yesterday it is worth remembering ==> The 51^st American Society of Hematology Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. This is labeled the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals-2009 ASH Annual Meeting abstracts, final program, and personal scheduler are now available online

 

DEC1st -DYAX the scheduled *FDA approval decision date for Kalbitor in hereditary angiodema  http://www.finviz.com/quote.ashx?t=dyax

 

DEC 2nd - EXEL Exelixis  analyst/investor meeting    http://www.finviz.com/quote.as.....=1&p=d

 

DEC 3rd - OSIP OSI Pharmaceuticals  analyst/investor meeting http://www.finviz.com/quote.as.....=1&p=d

 

Dec 4th - SOMX scheduled *FDA approval decision date for Somaxon Pharmaceutical’s Silenor in insomnia (note this one has been moving with vol)

http://www.finviz.com/quote.as.....=1&p=d

 

Dec 5th-8th American Society of Hematology Annual Meeting (ASH)

 

Dec 9th-13th San Antonio Breast Cancer Symposium - AACR American Association for  Cancer Research                  http://www.aacr.org/home/scien.....osium.aspx       

32nd Annual San Antonio Breast Cancer Symposium
“An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.”     http://www.sabcs.org/

 

Dec 10th - GILD the scheduled FDA advisory committee meeting for Gilead Sciences aztreonam lysine in cystic fibrosis                                       http://www.finviz.com/quote.as.....=1&p=d

 

DEC 10th - LLY Eli Lilly  analyst/investor meeting   http://www.finviz.com/quote.as.....=1&p=d

 

DEC 12th - VION.OB scheduled *FDA approval decision date for Vion Pharmaceuticals’ Onrigin in acute myelogenous leukemia

 

DEC 12th -IMGN  ImmunoGen and Roche: Results from phase II study of trastuzumab-DM1 in third-line metastatic breast cancer       http://www.finviz.com/quote.as.....=1&p=d

 

DEC 16th - OSIP  scheduled FDA advisory committee meeting for OSI Pharmaceuticals Tarceva in first-line non-small cell lung cancer  http://www.finviz.com/quote.ashx?t=OSIP

 

DEC 29th -  CEPH scheduled *FDA approval decision date for Cephalon  Nuvigil in jet lag disorder  http://www.finviz.com/quote.as.....=1&p=d

 

 

Additional important clinical trials with potential data readouts or other biotech expected events:

• Gilead Sciences: Results from a phase III study of darusentan in resistant hypertension
• AUXL and PFE -FDA approval decision date for Auxillium Pharmaceuticals Xiaflex for Dupuytren’s Contracture. (With Pfizer as marketing partner.)
• ARNA - Arena Pharmaceuticals submission of FDA approval application for lorcaserin in obesity
• BDSI - BioDelivery Sciences: Results from a phase II study of BEMA buprenorphine in dental pain
• SNTA - Synta Pharmaceuticals Results from a phase II study of apilimod in rheumatoid arthritis
• VVUS - Vivus submission of FDA approval application for Qnexa in obesity

http://www.finviz.com/quote.as.....=1&p=d

 

http://www.finviz.com/quote.as.....=1&p=d

 

http://www.finviz.com/quote.as.....=1&p=d

 

http://www.finviz.com/quote.as.....=1&p=d

 

http://www.finviz.com/quote.as.....=1&p=d

 

http://www.finviz.com/quote.as.....=1&p=d

 

 

Reference used : http://www.thestreet.com/story.....ember.html